Emma Andrus, Associate Editor

The TRACE study showed tralokinumab reduced genital AD severity and improved quality of life within 3 months of treatment.

Catch up on coverage from the second day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Expert tips from Whitney High, MD, at Elevate-Derm West 2024 guide experienced advanced practice providers in mastering dermatopathology and avoiding diagnostic pitfalls.

A poster presented at the 2024 Elevate-Derm West Conference outlines the pharmacokinetic profiles of spesolimab via intravenous and subcutaneous administration.

Catch up on coverage from the first day of the 2024 Elevate-Derm West Conference in Scottsdale, Arizona.

Roflumilast foam 0.3% significantly improved psoriasis severity, symptoms, and quality of life in patients with moderate to severe scalp and body psoriasis.

Apremilast led to a 75% improvement in PPPASI-75 in a significant portion of patients by week 16, with these improvements maintained through week 52.

The conference aimed at providing dermatology NPs and PAs with the latest in the specialty begins today in Scottsdale, Arizona.

We want to know: Will you be attending the conference in Scottsdale later this week?

The target action review date has been pushed to March 12, 2025.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

Dermatology Times is recapping our top expert interviews from the month of October.

Catch up on coverage from the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

In a Dermatology Times Case-Based Roundtable event, Pearl E. Grimes, MD, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

Manson Brown discusses Allergan Aesthetics' Science of Aging program, highlighting its role in shifting from anti-aging to pro-longevity in aesthetic medicine.

Belleson addresses one of the NEA's Eczema Awareness Month weekly themes, “The eczema community is here to inspire you.”

Discover top innovations, insights, and clinical pearls from Fall Clinical in Las Vegas, where dermatology’s biggest breakthroughs took center stage.

Deucravacitinib demonstrated significant efficacy and safety in treating moderate to severe scalp psoriasis, as shown in the PSORIATYK SCALP trial presented at Fall Clinical.

At Fall Clinical 2024, Graber spotlighted precise acne-targeting lasers, new combination creams, and a promising rosacea pill awaiting FDA approval.

Song shared top clinical tips at Fall Clinical, covering alopecia areata, refractory dermatoses, and novel non-steroidal topicals.

The recent meta-analysis revealed comparable efficacy in treating acne vulgaris and was presented at Fall Clinical 2024.

Catch up on coverage from the third day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

The phase 3b study shows Ebglyss reduced eczema severity and itch in challenging areas, with 60% of prior dupilumab patients meeting key improvement by week 24.

Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.

Sun Pharma presented long-term data on Leqselvi 8 mg tablets, showing significant scalp hair regrowth in severe alopecia areata patients.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Shahriari highlighted advanced dermatology treatments, clinical trial inclusivity, and key care strategies for complex skin conditions at Fall Clinical 2024.

Phase 3b study showed promise in clearing moderate PsO in sensitive areas for patients unresponsive to topical treatments.

Clinicians presented a panel-style session at Fall Clinical, touching on the drawbacks of topical steroid use and alternatives in AD patients.